Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants

perjantai 27. joulukuuta 2019 päivittänyt: GlaxoSmithKline

Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants

This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine, given as a 2-dose primary vaccination, in healthy Japanese infants aged approximately 2 months at the time of the first dose and previously uninfected with HRV. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis B (HBV) vaccines are allowed to be co-administered along with Rotarix vaccine/Placebo.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

765

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Aichi, Japani, 451-0052
        • GSK Investigational Site
      • Chiba, Japani, 275-8580
        • GSK Investigational Site
      • Fukuoka, Japani, 802-8533
        • GSK Investigational Site
      • Hiroshima, Japani, 720-8520
        • GSK Investigational Site
      • Hiroshima, Japani, 734-8530
        • GSK Investigational Site
      • Hiroshima, Japani, 737-0811
        • GSK Investigational Site
      • Hiroshima, Japani, 730-8518
        • GSK Investigational Site
      • Hiroshima, Japani, 730-8798
        • GSK Investigational Site
      • Hokkaido, Japani, 065-0033
        • GSK Investigational Site
      • Hokkaido, Japani, 003-0021
        • GSK Investigational Site
      • Kagawa, Japani, 765-8501
        • GSK Investigational Site
      • Kanagawa, Japani, 247-8533
        • GSK Investigational Site
      • Miyagi, Japani, 983-8520
        • GSK Investigational Site
      • Miyagi, Japani, 981-3203
        • GSK Investigational Site
      • Nagano, Japani, 386-8610
        • GSK Investigational Site
      • Nagasaki, Japani, 856-8562
        • GSK Investigational Site
      • Niigata, Japani, 957-8588
        • GSK Investigational Site
      • Okayama, Japani, 701-1192
        • GSK Investigational Site
      • Okayama, Japani, 701-0204
        • GSK Investigational Site
      • Osaka, Japani, 591-8025
        • GSK Investigational Site

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

1 kuukausi - 3 kuukautta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of age at the time of the first vaccination.
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Born between a gestation period of 36 and 42 weeks inclusive.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.
  • History of use of experimental rotavirus vaccine.
  • Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusception.
  • Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition determined by the investigator.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Previous confirmed occurrence of RV GE.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).
  • A family history of congenital or hereditary immunodeficiency.
  • Acute disease at the time of enrolment.
  • Gastroenteritis within 7 days preceding the study vaccine administration.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Rotarix Group
Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
Two-dose oral vaccination.
Placebo Comparator: Placebo Group
Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
Two-dose oral administration.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
Aikaikkuna: From 2 weeks after Dose 2 up to 2 years of age
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
From 2 weeks after Dose 2 up to 2 years of age

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
Aikaikkuna: From 2 weeks after Dose 2 up to 2 years of age
A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).
From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type
Aikaikkuna: From 2 weeks after Dose 2 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types
Aikaikkuna: From 2 weeks after Dose 2 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains
Aikaikkuna: From 2 weeks after Dose 2 up to 2 years of age
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
Aikaikkuna: From Dose 1 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From Dose 1 up to 2 years of age
Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration
Aikaikkuna: 2 months after Dose 2
Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).
2 months after Dose 2
Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies
Aikaikkuna: 2 months after Dose 2
Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.
2 months after Dose 2
Number of Subjects Reporting Solicited Symptoms
Aikaikkuna: During the 8-day follow-up period after each dose
Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.
During the 8-day follow-up period after each dose
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Aikaikkuna: During the 31-day follow-up period after each dose
Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
During the 31-day follow-up period after each dose
Number of Subjects Reporting Serious Adverse Events (SAEs)
Aikaikkuna: Up to 2 years of age
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Up to 2 years of age

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 19. kesäkuuta 2007

Ensisijainen valmistuminen (Todellinen)

Tiistai 31. maaliskuuta 2009

Opintojen valmistuminen (Todellinen)

Lauantai 21. marraskuuta 2009

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 29. toukokuuta 2007

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 29. toukokuuta 2007

Ensimmäinen Lähetetty (Arvio)

Keskiviikko 30. toukokuuta 2007

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 2. tammikuuta 2020

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 27. joulukuuta 2019

Viimeksi vahvistettu

Sunnuntai 1. joulukuuta 2019

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 107625
  • 2015-001543-36 (EudraCT-numero)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

IPD is available via the Clinical Study Data Request site (click on the link provided below)

IPD-jaon aikakehys

IPD is available via the Clinical Study Data Request site (click on the link provided below)

IPD-jaon käyttöoikeuskriteerit

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF
  • CSR

Tutkimustiedot/asiakirjat

  1. Ilmoitettu suostumuslomake
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register
  2. Tilastollinen analyysisuunnitelma
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register
  3. Yksittäisen osallistujan tietojoukko
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register
  4. Tutkimuspöytäkirja
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register
  5. Tietojoukon määritys
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register
  6. Selosteilla varustettu tapausraporttilomake
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register
  7. Kliinisen tutkimuksen raportti
    Tiedon tunniste: 107625
    Tietokommentit: For additional information about this study please refer to the GSK Clinical Study Register

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa